Perioperative chemotherapy in locally advanced gastric cancer;Quimioterapia perioperatório em câncer gástrico localmente avançado

Arquivos de Gastroenterologia

Volumn 50, Issue 3, 2013, Pages 236-242

  Batista, Thales Paulo ^a   de Santos, Candice Amorim Araújo Lima ^a   Almeida, Gustavo Fernandes Godoy ^a  

^a FPS IMIP   (Brazil)

Author keywords

Antineoplastic agents; Combined modality therapy; Drug therapy; Stomach neoplasms

Indexed keywords

CAPECITABINE PLUS OXALIPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; FOLLOW UP; GASTRECTOMY; HUMAN; LENGTH OF STAY; META ANALYSIS (TOPIC); MORBIDITY; MORTALITY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; REVIEW; STOMACH CANCER;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; NEOPLASM STAGING; STOMACH NEOPLASMS;

EID: 84885082641     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/S0004-28032013000200042     Document Type: Review

References (64)

1. Ajani JA, Rodriguez W, Bodoky G, Moiseyenko V, Lichinitser M, Gorbunova V, Vynnychenko I, Garin A, Lang I, Falcon S. Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fuorouracil in advanced gastric or gastro-esophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol. 2010;28:1547-1553.
2. An J Y, Kim KM, Kim YM, Cheong JH, Hyung WJ, Noh SH. Surgical Complications in Gastric Cancer Patients Preoperatively Treated with Chemotherapy: Their Risk Factors and Clinical Relevance. Ann Surg Oncol. 2012;19:2452-2458.
3. Arregi MM, Férrer DP, Assis EC, Paiva FD, Sobral LB, André NF, Silva TC. [Clinical - epidemiological profile of gastric neoplasms in the cancer Hospital of Ceara's Cancer Institute, from the period 2000-2004]. Rev Bras Cancerol. 2009;55:121-128.
4. Bajetta E, Buzzoni R, Mariani L, Beretta E, Bozzetti F, Bordogna G, Aitini E, Fava S, Schieppati G, Pinotti G, Visini M, Ianniello G, Di BM. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. Ann Oncol. 2002;13:299-307.
5. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with che motherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010.28;376:687-697.
6. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho J Y, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379:315-321.
7. Batista TP, Martins MR. Lymph node dissection for gastric cancer: a critical review. Oncology Reviews 2012; 6:e12.
8. Biff R, Fazio N, Luca F, Chiappa A, Andreoni B, Zampino MG, Roth A, Schull-er JC, Fiori G, Orsi F, Bonomo G, Crosta C, Huber O. Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World J Gastroenterol. 2010;16:868-874.
9. Bouché O, Ychou M, Burtin P, Bedenne L, Ducreux M, Lebreton G, Baulieux J, Nordlinger B, Martin C, Seitz JF, Tigaud JM, Echinard E, Stremsdoerfer N, Milan C, Rougier P; Fédération Francophone de Cancérologie Digestive Group. Adjuvant chemotherapy with 5-fuorouracil and cisplatin compared with surgery alone for gastric cancer: 7-year results of the FFCD randomized phase III trial (8801). Ann Oncol. 2005;16:1488-1497.
10. Brasil. Ministério da Saúde.[Internet]. Estimation 2012: cancer incidence in Brazil. Rio de Janeiro, National Cancer Institute (INCA), 2011. [cited 2012 May 7]. Available from: http://www.inca.gov.br/estimativa/2012/.
11. Campelo JC, Lima LC. [Clinical and epidemiological profile of early gastric cancer in a Referral Hospital in Teresina, Piauí]. Rev Bras Cancerol. 2012;58:15-20.
12. Cascinu S, Labianca R, Barone C, Santoro A, Carnaghi C, Cassano A, Beretta GD, Catalano V, Bertetto O, Barni S, Frontini L, Aitini E, Rota S, Torri V, Flo-riani I, Pozzo C, Rimassa L, Mosconi S, Giordani P, Ardizzoia A, Foa P, Rabbi C, Chiara S, Gasparini G, Nardi M, Mansutti M, Arnoldi E, Piazza E, Cortesi E, Pucci F, Silva RR, Sobrero A, Ravaioli A. Italian Group for the Study of Digestive Tract Cancer, Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fuorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial. J Natl Cancer Inst. 2007;99:601-607.
13. Chen XZ, Yang K, Liu J, Chen XL, Hu JK. Neoadjuvant plus adjuvant chemotherapy benefts overall survival of locally advanced gastric cancer. World J Gastroenterol. 2011 17(40):4542-4544.
14. Chipponi J, Huguier M, Pezet D, Basso N, Hay JM, Quandalle P, Jaeck D, Fag-niez PL, Gainant A. Randomized trial of adjuvant chemotherapy after curative resection for gastric cancer. Am J Surg. 2004;187:440-445.
15. Chuah B, Goh BC, Lee SC, Soong R, Lau F, Mulay M, Dinolfo M, Lim SE, Soo R, Furuie T, Saito K, Zergebel C, Rosen LS. Comparison of the pharmacokinetics and pharmacodynamics of S-1 between Caucasian and East Asian patients. Cancer Sci. 2011;102:478-483.
16. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nic-olson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
17. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR and Kingdom, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36-46.
18. De Vita F, Giuliani F, Galizia G, Belli C, Aurilio G, Santabarbara G, Ciardiello F, Catalano G, Orditura M. Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Ann Oncol. 2007;18 Suppl 6:vi120-vi123.
19. Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, et al. Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC. J Natl Cancer Inst. 2008;100:388-398.
20. Everett SM, Axon AT. Early gastric cancer in Europe. Gut. 1997;41:142-150.
21. Fazio N, Biff R, Curigliano G, Lorizzo K, Zampino MG, de Braud F, Chiappa A, Roth A, Goldhirsch A. Re: Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fuorouracil, leucovorin, cisplatin, and epidoxoru-bicin in a randomized controlled trial. J Natl Cancer Inst. 2007;99:1345-1346.
22. Ferri LE, Ades S, Alcindor T, Chasen M, Marcus V, Hickeson M, Artho G, Thirlwell MP. Perioperative docetaxel, cisplatin, and 5-fuorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Ann Oncol. 2012;23:1512-1517.
23. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729-37.
24. Guimarães RM, Muzi CD. Trend of mortality rates for gastric cancer in Brazil and regions in the period of 30 years (1980-2009). Arq Gastroenterol. 2012;49:184-188.
25. Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643-649.
26. Hu JK, Chen ZX, Zhou ZG, Zhang B, Tian J, Chen JP, Wang L, Wang CH, Chen H Y, Li YP. Intravenous chemotherapy for resected gastric cancer: meta-analysis of randomized controlled trials. World J Gastroenterol. 2002;8:1023-1028.
27. Hu JK, Li CM, Chen XZ, Chen ZX, Zhou ZG, Zhang B, Chen JP. The effectiveness of intravenous 5-fuorouracil-containing chemotherapy after curative resection for gastric carcinoma: A systematic review of published randomized controlled trials. J Chemother. 2007;19:359-375.
28. Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597-608.
29. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
30. Jeung HC, Rha SY, Shin SJ, Ahn JB, Roh JK, Park CH, Noh SH, Chung HC. Postoperative adjuvant chemotherapy of gastric cancer: scrutiny into the clinical evidence based on quality assessment of medical literature of randomized controlled trials. Cancer Chemother Pharmacol. 2009;63:919-927.
31. Kilickap S, Yalcin S, Ates O, Tekuzman G. The first line systemic chemotherapy in metastatic gastric carcinoma: A comparison of docetaxel, cisplatin and fuo-rouracil (DCF) versus cisplatin and fuorouracil (CF); versus epirubicin, cisplatin and fuorouracil (ECF) regimens in clinical setting. Hepatogastroenterology. 2011;58:208-212.
32. Kulig J, Kolodziejczyk P, Sierzega M, Bobrzynski L, Jedrys J, Popiela T, Dadan J, Drews M, Jeziorski A, Krawczyk M, Starzynska T, Wallner G. Adjuvant chemotherapy with etoposide, adriamycin and cisplatin compared with surgery alone in the treatment of gastric cancer: a phase III randomized, multicenter, clinical trial. Oncology. 2010;78:54-61.
33. Li W, Qin J, Sun YH, Liu TS. Neoadjuvant chemotherapy for advanced gastric cancer: a meta-analysis. World J Gastroenterol. 2010;16:5621-5628.
34. Li ZY, Shan F, Zhang LH, Bu ZD, Wu AW, Wu XJ, Zong XL, Wu Q, Ren H, Ji JF. Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World J Surg Oncol. 2011;9:110.
35. Liu TS, Wang Y, Chen SY, Sun YH. An updated meta-analysis of adjuvant chemotherapy after curative resection for gastric cancer. Eur J Surg Oncol. 2008;34:1208-1216.
36. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA. Chemo-radiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725-730.
37. Marutsuka T, Shimada S, Shiomori K, Hayashi N, Yagi Y, Yamane T, Ogawa M. Mechanisms of peritoneal metastasis after operation for non-serosa-invasive gastric carcinoma: an ultrarapid detection system for intraperitoneal free cancer cells and a prophylactic strategy for peritoneal metastasis. Clin Cancer Res. 2003;9:678-685.
38. Miyazono F, Natsugoe S, Takao S, Tokuda K, Kijima F, Aridome K, Hokita S, Baba M, Eizuru Y, Aikou T. Surgical maneuvers enhance molecular detection of circulating tumor cells during gastric cancer surgery. Ann Surg. 2001;233:189-194.
39. Muraro CL. Early gastric cancer: contribution to diagnosis and results of surgical treatment. Rev Col Bras Cir. 2003;30:352-358.
40. Nakajima T, Kinoshita T, Nashimoto A, Sairenji M, Yamaguchi T, Sakamoto J, Fujiya T, Inada T, Sasako M, Ohashi Y and Group, National Surgical Adjuvant Study of Gastric Cancer. Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer. Br J Surg. 2007;94:1468-1476.
41. Nashimoto A, Nakajima T, Furukawa H, Kitamura M, Kinoshita T, Yamamura Y, Sasako M, Kunii Y, Motohashi H, Yamamoto S and Gastric Cancer Surgical Study Group, Japan Clinical Oncology Group. Randomized trial of adjuvant chemotherapy with mitomycin, fuorouracil, and cytosine arabinoside followed by oral fuorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1. J Clin Oncol. 2003;21:2282-2287.
42. Nitti D, Wils J, Dos Santos JG, Fountzilas G, Conte PF, Sava C, Tres A, Coombes RC, Crivellari D, Marchet A, Sanchez E, Bliss JM, Homewood J, Couvreur ML, Hall E, Baron B, Woods E, Emson M, Van Cutsem E, Lise M, EORTC GI Group; ICCG. Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG. Ann Oncol. 2006;17:262-269.
43. Oba K, Morita S, Tsuburaya A, Kodera Y, Kobayashi M, Sakamoto J. Efficacy of adjuvant chemotherapy using oral fuorinated pyrimidines for curatively resected gastric cancer: a meta-analysis of centrally randomized controlled clinical trials in Japan. J Chemother. 2006;18:311-317.
44. Oba K. Efficacy of adjuvant chemotherapy using tegafur-based regimen for curatively resected gastric cancer: update of a meta-analysis. Int J Clin Oncol. 2009;14:85-89.
45. Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188-96.
46. Ohtsu A. Diverse eastern and Western approaches to the management of gastric cancer. Gastrointest Cancer Res. 2007;1:S10-S15.
47. Panzini I, Gianni L, Fattori P P, Tassinari D, Imola M, Fabbri P, Arcangeli V, Drudi G, Canuti D, Fochessati F, Ravaioli A. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses. Tumori. 2002;88:21-27.
48. Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi FC, Schinzari G, D'Ugo D. 7-Year survival results of perioperative chemotherapy with epidoxoru-bicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol. 2008;15:2146-2152.
49. Popiela T, Kulig J, Czupryna A, Szczepanik AM, Zembala M. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004;7:240-245.
50. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC. Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fuoropyrimidine. N Engl J Med. 2007;357:1810-1820.
51. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387-4393.
52. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberg-er CF, Haag C, Mauer ME, Hasan B, Welch J, Ott K, Hoelscher A, Schneider PM, Bechstein W, Wilke H, Lutz MP, Nordlinger B, Van Cutsem E, Siewert JR, Schlag PM. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organization for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210-5218.
53. Shitara K, Sawaki A, Matsuo K, Kondo C, Takahari D, Ura T, Tajika M, Niwa Y, Muro K. A retrospective comparison of S-1 plus cisplatin and capecitabine plus cisplatin for patients with advanced or recurrent gastric cancer. Int J Clin Oncol. 2012. [Epub ahead of print].
54. Songun I, Keizer HJ, Hermans J, Klementschitsch P, de Vries JE, Wils JA, van der Bijl J, van Krieken JH, van de Velde CJ. Chemotherapy for operable gastric cancer: results of the Dutch randomised FAMTX trial. The Dutch Gastric Cancer Group (DGCG). Eur J Cancer. 1999;35:558-562.
55. Sumpter K, Harper-Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, Ward C, Iveson T, Nicolson M, Hickish T, Hill M, Oates J. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fuorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92:1976-1983.
56. Sun P, Xiang JB, Chen ZY. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. Br J Surg. 2009;96:26-33.
57. Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, Graeven U, Lokich J, Madajewicz S, Maroun JA, Marshall JL, Mitchell EP, Perez-Manga G, Rougier P, Schmiegel W, Schoelmerich J, Sobrero A, Schilsky RL. Oral capecitabine vs intravenous 5-fuorouracil and leucovorin: integrated effcacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer. 2004;90:1190-1197.
58. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA; V325 Study Group. Phase III study of docetaxel and cisplatin plus fuorouracil compared with cisplatin and fuorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24:4991-4997.
59. Van Cutsem E, Van de Velde C, Roth A, Lordick F, Köhne CH, Cascinu S, Aapro M, European Organisation for Research and Treatment of Cancer (EO-RTC)-gastrointestinal cancer group. Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer. 2008;44:182-194.
60. Vinagre RM, Campos BP, Sousa RM. Case study of stomach adenocarcinoma conducted at a cancer referral hospital in northern Brazil. Arq Gastroenterol. 2012;49:125-129.
61. Yamaguchi K, Sawaki A, Doi T, Satoh T, Yamada Y, Omuro Y, Nishina T, Boku N, Chin K, Hamamoto Y, Takiuchi H, Komatsu Y, Saji S, Koizumi W, Miyata Y, Sato A, Baba E, Tamura T, Abe T, Ohtsu A. Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 2013;16:183-184.
62. Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P. Periopera-tive chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715-1721.
63. Zhao SL, Fang JY. The role of postoperative adjuvant chemotherapy following curative resection for gastric cancer: a meta-analysis. Cancer Invest. 2008;26:317-325.
64. Zilberstein B, Jacob CE, Cecconello I. Gastric cancer trends in epidemiology. Arq Gastroenterol. 2012;49:177-178.